PURPOSE: To evaluate the impact of hypofractionated boost after hypofractionated whole breast irradiation in breast carcinoma. METHODS AND MATERIALS: Patients after breast conservative surgery were treated all time with hypofractionation of 2.67 Gy/day. Whole breast dose was 40.05 Gy followed in case of risk of local relapse by a boost of 16.02 Gy or 8.01 Gy. Acute and chronic toxicity results were evaluated including cosmetic software-assisted assessment and objective evaluation of fibrosis parameters (elasticity and hydration) by means of a skin tester. RESULTS: A total of 362 patients were evaluated. Acute toxicities comprised grade 1 dermatitis in 48.1 %, grade 2 in 44.5 % and grade 3 in 17 patients 4.7 %, respectively. After a median f...
Aims: To report the 5- and 10-year results of accelerated hypofractionated whole-breast radiotherapy...
Purpose/Objective(s): Randomized clinical trials support the use of hypofractionated whole breast ir...
Purpose To evaluate toxicity in breast cancer patients treated with anthracycline and taxane based c...
PURPOSE: To evaluate the impact of hypofractionated boost after hypofractionated whole breast irradi...
Objectives:The aim of this study is to evaluate the feasibility and the related toxicity of hypofrac...
Purpose: Hypofractionated radiation therapy (HFRT) remains underused, despite multiple randomized tr...
Whole-breast irradiation after conservative surgery is the standard treatment for early breast cance...
Accelerated hypofractionation (HF) using larger dose per fraction, delivered in fewer fractions over...
Background: The high number of breast cancer patients who receive radiation therapy after surgery ha...
The aim of this study was to evaluate local control, survival and toxicity profile of a consecutive ...
PURPOSE: To evaluate toxicity and cosmetic outcome (CO) in breast cancer survivors treated with thre...
Purpose: To evaluate toxicity and cosmetic outcome (CO) in breast cancer survivors treated with thre...
© 2016 Elsevier Inc. Purpose Conventionally fractionated whole-breast irradiation (WBI) with a boost...
In the present study participated 54 patients (mean age 56 ± 9). 39 of 54 patients (72,2%), had tumo...
Objective: to compare cosmetic result of two techniques of boost delivery to the tumor bed after bre...
Aims: To report the 5- and 10-year results of accelerated hypofractionated whole-breast radiotherapy...
Purpose/Objective(s): Randomized clinical trials support the use of hypofractionated whole breast ir...
Purpose To evaluate toxicity in breast cancer patients treated with anthracycline and taxane based c...
PURPOSE: To evaluate the impact of hypofractionated boost after hypofractionated whole breast irradi...
Objectives:The aim of this study is to evaluate the feasibility and the related toxicity of hypofrac...
Purpose: Hypofractionated radiation therapy (HFRT) remains underused, despite multiple randomized tr...
Whole-breast irradiation after conservative surgery is the standard treatment for early breast cance...
Accelerated hypofractionation (HF) using larger dose per fraction, delivered in fewer fractions over...
Background: The high number of breast cancer patients who receive radiation therapy after surgery ha...
The aim of this study was to evaluate local control, survival and toxicity profile of a consecutive ...
PURPOSE: To evaluate toxicity and cosmetic outcome (CO) in breast cancer survivors treated with thre...
Purpose: To evaluate toxicity and cosmetic outcome (CO) in breast cancer survivors treated with thre...
© 2016 Elsevier Inc. Purpose Conventionally fractionated whole-breast irradiation (WBI) with a boost...
In the present study participated 54 patients (mean age 56 ± 9). 39 of 54 patients (72,2%), had tumo...
Objective: to compare cosmetic result of two techniques of boost delivery to the tumor bed after bre...
Aims: To report the 5- and 10-year results of accelerated hypofractionated whole-breast radiotherapy...
Purpose/Objective(s): Randomized clinical trials support the use of hypofractionated whole breast ir...
Purpose To evaluate toxicity in breast cancer patients treated with anthracycline and taxane based c...